JPMorgan Chase & Co. Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its target price cut by JPMorgan Chase & Co. from $173.00 to $116.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock.

TMDX has been the topic of several other reports. Canaccord Genuity Group lowered their price objective on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday. Robert W. Baird lowered their price target on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday. Needham & Company LLC cut their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Oppenheimer lowered their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Trading Up 0.1 %

Shares of NASDAQ TMDX opened at $81.97 on Tuesday. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 8.48. The firm has a 50-day moving average of $142.38 and a 200 day moving average of $139.36. The stock has a market cap of $2.75 billion, a P/E ratio of 87.20 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, sell-side analysts expect that TransMedics Group will post 1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total value of $1,012,230.00. Following the sale, the director now owns 732 shares of the company’s stock, valued at approximately $109,770.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 over the last 90 days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently added to or reduced their stakes in TMDX. Vanguard Group Inc. increased its position in shares of TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after purchasing an additional 50,673 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after purchasing an additional 30,092 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in TransMedics Group during the 2nd quarter valued at approximately $1,400,000. Handelsbanken Fonder AB raised its holdings in shares of TransMedics Group by 657.6% in the third quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock worth $10,111,000 after buying an additional 55,900 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after buying an additional 26,997 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.